Early plasma treatment may slow Covid-19 progression in older adults
In short: A study of 160 older adults with mild Covid-19 symptoms found that receiving high-titer convalescent plasma early in the illness reduced the risk of developing severe respiratory disease. Researchers observed that those who received the plasma were significantly less likely to experience severe symptoms compared to those given a placebo.
The study aimed to see if administering antibodies from recovered patients could interrupt the disease's progression. By treating patients within 72 hours of symptom onset, the team sought a more effective window for intervention than late-stage hospital treatments.
The trial was stopped early because local infection rates dropped, making enrollment difficult. While the results were promising, the study's small sample size and early termination are important considerations for interpreting the broader impact.
Why it matters: Timing matters in treatment; early intervention with convalescent plasma may help prevent severe illness in high-risk groups.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Source: Research: Libster et al. (2021). Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. New England Journal of Medicine. · cc-by
To cite this card, link to https://intellectplus.co.uk/app/health-research-early-plasma-treatment-may-slow-covid-19-progression-in-olde.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Pandemics & epidemics · More in Health · Latest · A–Z · All topics
